← Leaderboards
Mark S. Segal
Veterans Health Administration
$4,796,427
Attributed
$6,343,733
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,343,733 · 7
VA$0 · 2
By mechanism
T32$2,377,570 · 2
R01$2,152,177 · 2
P50$1,293,956 · 1
K08$375,030 · 1
R03$145,000 · 1
I01$0 · 2
Top collaborators
- Ashutosh M Shukla7 shared
- Charles E Wood5 shared
- Carl J Pepine4 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Kamyar Kalantar-Zadeh$11,734,421
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyInflammationCardiovascular SystemCardiovascular DiseasesAffectHypertensionChronic Kidney FailureEnrollmentAnimal ModelCardiacAnimalsInflammatoryInsightFutureSample SizeMortalityEndotheliumBlood VesselsMediatingCellsBaseCardiovascular Risk FactorCarotid Artery PlaquesAtherosclerosis
Grant awards (36)
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2025 · VA
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2024 · VA
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2023 · VA
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2022 · VA
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2021 · VA
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2020 · VA
Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease$0
I01 · FY2020 · VA · contact PI
REnal TrAIning & reteNtion (RETAIN) Program$332,808
T32 · FY2019 · DK · contact PI
Hydroxychloroquine for the Management of CVD in CKD$0
I01 · FY2019 · VA
Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease$0
I01 · FY2019 · VA · contact PI
REnal TrAIning & reteNtion (RETAIN) Program$334,549
T32 · FY2018 · DK · contact PI
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS$256,154
P50 · FY2018 · GM · contact PI
Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease$0
I01 · FY2018 · VA · contact PI
REnal TrAIning & reteNtion (RETAIN) Program$320,984
T32 · FY2017 · DK · contact PI
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS$257,929
P50 · FY2017 · GM · contact PI
REnal TrAIning & reteNtion (RETAIN) Program$317,018
T32 · FY2016 · DK · contact PI
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS$257,015
P50 · FY2016 · GM · contact PI
REnal TrAIning & reteNtion (RETAIN) Program$308,689
T32 · FY2015 · DK · contact PI
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS$231,717
P50 · FY2015 · GM · contact PI
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS$291,141
P50 · FY2014 · GM · contact PI
Ancillary Functional Studies for the CCTRN$367,235
R01 · FY2011 · HL
Pre & Post-Doctoral Training in Nephrology & Hypertension$101,291
T32 · FY2011 · DK · contact PI
Pre & Post-Doctoral Training in Nephrology & Hypertension$36,525
T32 · FY2011 · DK · contact PI
Ancillary Functional Studies for the CCTRN$367,235
R01 · FY2010 · HL
Pre & Post-Doctoral Training in Nephrology & Hypertension$223,205
T32 · FY2010 · DK · contact PI
Ancillary Functional Studies for the CCTRN$367,235
R01 · FY2009 · HL
Pre & Post-Doctoral Training in Nephrology & Hypertension$223,428
T32 · FY2009 · DK · contact PI
Uric Acid and Hypertension in African-Americans$671,612
R01 · FY2008 · HL · contact PI
Ancillary Functional Studies for the CCTRN$378,860
R01 · FY2008 · HL
Pre & Post-Doctoral Training in Nephrology & Hypertension$179,073
T32 · FY2008 · DK · contact PI
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS$1,080
K08 · FY2003 · DK
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS$128,250
K08 · FY2002 · DK
Ionic Charge and pH Regulation of Apoptotic Signaling$72,500
R03 · FY2002 · DK
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS$122,850
K08 · FY2001 · DK
Ionic Charge and pH Regulation of Apoptotic Signaling$72,500
R03 · FY2001 · DK
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS$122,850
K08 · FY2000 · DK